Impacting tumor cell-fate by targeting the inhibitor of apoptosis protein survivin

摘要: Survivin (BIRC5), a member of the inhibitor apoptosis protein (IAP) family that inhibits caspases and blocks cell death is highly expressed in cancer associated with poorer clinical outcome. Functioning simultaneously during division inhibition, survivin plays pivotal role determining survival. has consistently been identified by molecular profiling analysis to be higher tumor grade, more advanced disease, abbreviated survival, accelerated rates recurrence, chemotherapy radiation resistance. Survivin's differential expression compared normal tissue its as nodal number cellular pathways make it flexible therapeutic target, suitable for small-molecule inhibitiors, antagonists, vaccination-based therapies. By targeting hoped multiple signaling circuitries may disabled. This effect applicable many histologies irrespective specific genetic makeup. To date, inhibitors have shown modest activity single agents, but anticipated when given combination cytotoxic or monoclonal antibodies they exhibit enhanced efficacy. review discusses complex circuitry human cancers highlights trials involving novel agents target this important protein.